Natco Gets US Front-End Through Dash Acquisition
Indian Firm’s $18m Deal For US Company Represents Potential Strategy Shift
Executive Summary
India’s Natco Pharma has struck an $18m deal to acquire New Jersey-based Dash Pharmaceuticals in a bid to acquire a “direct front-end marketing footprint” in the US.
You may also be interested in...
Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing
Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.
Sun Settles On Revlimid As Natco Scoops First ANDA Approval
Sun Pharma has become the latest ANDA sponsor to settle litigation with Celgene over Revlimid, shortly after Natco and partner Teva picked up the first ANDA approval for the blockbuster treatment for multiple myeloma.
Breckenridge Eyes First Kyprolis Generic With FDA Approval
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.